For the past couple of years, interest in cannabidol (CBD) has been gaining traction in Europe and the U.S., mostly caused by the cannabis extract’s abilities as a versatile natural medication. Although there has been little conclusive scientific research on the efficacy and side effects of CBD, there is plenty of anecdotal evidence claiming it is effective against a host of medical conditions ranging from anxiety to chronic pain and high blood pressure. Now it seems that cannabidiol has another use up its sleeve.
The subject of cannabinoids and dementia, and whether CBD can be used to alleviate common age-related medical conditions was tabled at a debate in Rio de Janeiro, promoted by the Brazilian Society of Geriatrics and Gerontology (SBGG). International case studies on cannabinoids and dementia were presented by Ivan Abdalla, a physician at…
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.